What are the six most influential factors in pharmacovigilance?

The development of new pharmaceutical products is heavily reliant on pharmacovigilance. It guarantees that these goods are used safely and efficiently to improve patients’ health. Due to increasingly strict rules and the growing significance of patient-centricity, pharmacovigilance is now much more important than it was formerly. The industry’s current pharmacovigilance trends are outlined in detail.

1. Driving efficiency and profitability through procuring

Pharmacovigilance-specific outsourcing is becoming increasingly popular as a means of coping with the rising cost of keeping an internal workforce that is highly skilled and trained.

An effective pharmacovigilance outsourcing program has measurable advantages for manufacturers and sponsors. Businesses nowadays outsource their pharmacovigilance work to improve regulatory compliance, quality, productivity, and strategic decisions. 

2. Early assessment of safety concerns using qualitative and quantitative data 

Secondary data sources have multiplied over the past few years and at this time includes:

Social networking, computerized medical records, and claims files. Regulatory reports and documents filed by various authorities. 

The gathering and integration of secondary data sources with traditional datasets present special difficulties. From a regulatory standpoint, pharmaceutical companies are now just at the beginning stages of their use of secondary data.

However, initiatives like the Sentinel Initiative of the FDA and WEB-RADR of the EMA demonstrate the interest that regulatory bodies have in the utilization of secondary data.

Technology vendors have recently begun to provide reliable and adaptable systems that aid life sciences organizations in handling and integrating a variety of file kinds and integrating social media streams into their pharmacovigilance operations.

Social media streams are being added to the scope of sophisticated algorithms and disproportionality analysis, in addition to conventional spontaneous reporting.

The combination of secondary data sources and cutting-edge signal detection technologies enables the quicker identification of safety issues and the implementation of risk reduction measures.

3. Cloud-based Data to Create a Powerful Global Adverse Event Network 

Massive volumes of data can now be stored and analyzed in the cloud, which is advantageous for many sectors. Life sciences organizations must optimize the intake, storage, and analysis of large volumes of data as the number of data sources increases.

Moving to the cloud is primarily motivated by:

Cost-effectiveness: Using the cloud may allow businesses to deal with a large volume of case data while maintaining quality, security, and data privacy. 

Scalability: The volume of adverse event cases for life science firms has been increasing rapidly, with some firms reporting a yearly increase. This increase necessitates the use of equipment that can easily handle the growing volume of data.

By letting firms avoid concerns about module compatibility and server scale, cloud utilization can make life simpler for them.

4. Protection and assimilation of vast amounts of information using big data

In recent times, pharmacovigilance specialists have gained access to new digital sources of experimental data and real-world evidence.

Big data sources used in pharmacovigilance include:

Signal identification; confirmation and substantiation of safety signals for drugs or vaccines; online channels and social media. 

Because of its complexity, big data represents both a challenge and an opportunity. Life sciences firms employ big data to better effectively monitor and research drug safety thanks to technological advancements with high-end computer capabilities.

5. Data Analytics to Drive Useful Understanding

For a comprehensive knowledge of safety occurrences, it is essential to handle safety data collected across numerous platforms effectively. A rising number of life sciences organizations use cutting-edge pharmacovigilance techniques to analyze vast and diverse data sets, including safety information. To safeguard the safety of their patients more effectively, they work to identify novel patterns, unrecognized correlations, trends, and patient preferences.

These days, pharmacovigilance analytics offers a real chance to successfully harness data, assure regulatory compliance, and generate useful insights.

6. Streamlining Non-Value-Adding Activities in Pharmacovigilance Functions

Companies in the life sciences industry are actively seeking solutions to cut down on the rising cost of pharmacovigilance and the likelihood of human mistakes in pharmacovigilance jobs. Automation is a key component that can assist companies in achieving both objectives by:

Streamlining the entire safety procedure

removing unnecessary steps from the existing procedure

improving team productivity.

Life sciences organizations have an increasing number of opportunities to incorporate automation into their routine pharmacovigilance activities as regulatory bodies roll out new tools to gather and analyze adverse occurrences.

Sollers College will assist you at every step of the journey. We are your first point of contact for any support you may require. Sollers gives you any information you need about your career.